AYTU BIOPHARMA, INC Proceeds from Sale of Productive Assets
AYTU BIOPHARMA, INC (AYTU) reported Proceeds from Sale of Productive Assets of $0 for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2026-09-22
- AYTU BIOPHARMA, INC proceeds from sale of productive assets for the quarter ending 2026-06-30 was $0.00.
- AYTU BIOPHARMA, INC proceeds from sale of productive assets for the quarter ending 2026-03-31 was $0.00.
- AYTU BIOPHARMA, INC proceeds from sale of productive assets for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC proceeds from sale of productive assets for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC proceeds from sale of productive assets for fiscal 2026 was $0.00, a 100.00% decline from fiscal 2025.
- AYTU BIOPHARMA, INC proceeds from sale of productive assets for fiscal 2025 was $668.00K.
- AYTU BIOPHARMA, INC proceeds from sale of productive assets for fiscal 2024 was $0.00.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 9 month | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $0.00 10-K · filed 2026-09-22 |
| 2026-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03 | $0.00 10-Q · filed 2026-02-03 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $0.00 derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $151.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $151.00K derived: sum of 3 quarters · filed 2026-09-22 | $668.00K 10-K · filed 2026-09-22 |
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | $151.00K derived: sum of 2 quarters · filed 2026-05-13 | $668.00K 10-Q · filed 2026-05-13 | $668.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03 | $668.00K 10-Q · filed 2026-02-03 | $668.00K derived: sum of 3 quarters · filed 2026-02-03 | $668.00K derived: sum of 4 quarters · filed 2026-02-03 |
| 2024-09-30 | $517.00K 10-Q · filed 2025-11-13 | $517.00K derived: sum of 2 quarters · filed 2025-11-13 | $517.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $0.00 derived: sum of 2 quarters · filed 2025-09-23 | $0.00 10-K · filed 2025-09-23 | |
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | $0.00 10-Q · filed 2025-05-14 | ||
| 2023-12-31 | $0.00 10-Q · filed 2025-02-12 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |